Studio clinico NCT07063745 · Metastatic Non-small Cell Lung Cancer With MTAP Deletion

Studio clinico NCT07063745 (fase II/III) risulta «in reclutamento» su ClinicalTrials.gov.

Patologia: Metastatic Non-small Cell Lung Cancer With MTAP Deletion · Interventi registrati: BMS-986504, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel · Date registrate (fonte): 2026-01-02, 2031-08-12, 2025-07-14, 2026-10-23.

Sintesi dello studio (fonte: ClinicalTrials.gov, testo originale in inglese):

The purpose of this study is to compare the clinical benefit of the combination of Navlimetostat (BMS-986504) (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemotherapy in first-line metastatic non-small cell lung cancer participants with homozygous MTAP deletion

Fonte: https://clinicaltrials.gov/study/NCT07063745